Varsha Kontham Kulangara, Nagarkatti Mitzi, Nagarkatti Prakash
Department of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, SC, United States.
Adv Drug Alcohol Res. 2022;2. doi: 10.3389/adar.2022.10550. Epub 2022 Jul 14.
Cannabinoids and the endocannabinoid system have been well established to play a crucial role in the regulation of the immune response. Also, emerging data from numerous investigations unravel the imperative role of gut microbiota and their metabolites in the maintenance of immune homeostasis and gut barrier integrity. In this review, we concisely report the immunosuppressive mechanisms triggered by cannabinoids, and how they are closely associated with the alterations in the gut microbiome and metabolome following exposure to endogenous or exogenous cannabinoids. We discuss how cannabinoid-mediated induction of microbial secondary bile acids, short chain fatty acids, and indole metabolites, produced in the gut, can suppress inflammation even in distal organs. While clearly, more clinical studies are necessary to establish the cross talk between exo- or endocannabinoid system with the gut microbiome and the immune system, the current evidence opens a new avenue of cannabinoid-gut-microbiota-based therapeutics to regulate immunological disorders.
Adv Drug Alcohol Res. 2022
Neurobiol Pain. 2021-2-16
Nat Rev Endocrinol. 2015-12-18
Gastroenterology. 2023-6
ACS Pharmacol Transl Sci. 2025-3-26
Int J Mol Sci. 2024-1-10
Pharmaceuticals (Basel). 2022-3-10
Front Pharmacol. 2022-2-4
Int J Mol Sci. 2021-12-28
Cells. 2021-11-2
Front Endocrinol (Lausanne). 2021